September 14, 2017 / 8:31 PM / in 3 months

BRIEF-Janssen submits supplemental New Drug Application to U.S. FDA for Zytiga

Sept 15 (Reuters) - Johnson & Johnson

* Janssen submits supplemental New Drug Application to U.S. FDA for Zytiga® (abiraterone acetate) to treat men with earlier stages of metastatic prostate cancer

* Janssen - announced submission of supplemental New Drug Application to U.S. FDA seeking to expand indication of Zytiga Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below